Omega announces that following completion of the of US performance studies, its technology partner, Mologic Ltd has filed its submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorisation for its rapid point-of-care COVID-19 antigen test, for use under both the Omega’s VISITECT® brand and Global Access Diagnostics (GAD) brand.
Read the full RNS here